Event will feature insights on LX9211, Lexicon’s novel, investigational, non-opioid treatment, as well as expert panel and Q&A session on DPNPTHE WOODLANDS, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE ...
During the last three months, 8 analysts shared their evaluations of Lexicon Pharmaceuticals LXRX, revealing diverse outlooks from bullish to bearish. The following table provides a quick overview ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback